## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application Of:	)	
Mark J. Cooper et al.	)	Group Art No.: TBA
Serial No: TBA	)	Examiner: TBA
Filed: September 8, 2003	)	Docket No.: 03659.00029

For: LYOPHILIZABLE AND ENHANCED COMPACTED NUCLEIC ACIDS

## **INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, enclosed is a PTO Form 1449 listing documents for consideration by the Examiner in the subject application. Copies of the cited references were submitted in parent Application No. 09/867,693 or were provided by the Examiner attached to an Office Action. No fee is believed to be due to ensure consideration and entry of the cited documents by the Examiner. However, if a fee is deemed necessary, the Commissioner is authorized to charge our Deposit Account No. 19-0733.

Respectfully submitted,

Dated: September 8, 2003

Michelle L. Holmes-Son Registration No. 47,660

BANNER & WITCOFF, LTD. 1001 G Street, N.W., 11<sup>th</sup> Floor Washington, D.C. 20001

TEL: (202) 824-3000 FAX: (202) 824-3001

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	te for form 1449A/PTO			Complete if Known	
NFC	DRMATION DI	SCLOSURE	Application Number	ТВА	
	TEMENT BY		Filing Date	September 8, 2003	
917		AI I EIOAII	First Named Inventor	Mark COOPER	
			Group Art Unit	TBA	
	(use as many sheets	as necessary)	Examiner Name	TBA	
heet	1 0	f 2	Attorney Docket Number	003650 00030	

			U.S. PATENT	OCUMENTS	
Examiner Initials *	Cite No.1	Document Number  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		5,656,611	08/12/1997	Kabanov, et al.	Тідагоз дереса
		5,844,107	12/01/1998	Hanson, et al.	
		6,177,274	01/23/2001	Park, et al.	
			<del></del>		

	FOREIGN PATENT DOCUMENTS					
Examiner	Cite	Foreign Patent Document	D. N. Santan	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		EP 1031626	08/30/2000	Erbacher, et al.		
		WO 97/30731	08/28/1997	Lollo, et al.		
		WO 98/46274	10/28/1998	Burgess, et al.		
		WO 98/19710	05/14/1998	Schacht, et al.		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	e for form 144	9A/PTO				Complete if Known	1
WE0		ON DI	20100	DE	Application Number	TBA	
	RMATI				Filing Date	September 8, 2003	
STA	TEMEN	TBYA	PPLIC	CANT	First Named Inventor	Mark COOPER	
					Group Art Unit	TBA	
	(use as ma	ny sheets a	is necessai	ry)	Examiner Name	TBA	
Sheet	2	of	2		Attorney Docket Number	003659.00029	J

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ2
		Aberle, et al., "The counterion influence on cationic lipid-mediated transfection of plasmid DNA", Biochemica et Biophysica Acta, 1996, pages 281-283, Elsevier Science B.V.	
		Allison, et al., "Mechanisms of Protection of Cationic Lipid-DNA Complexes During Lyophilization", Journal of Pharmaceutical Sciences, 2000, pages 682-691, vol. 89, no. 5, Wiley-Liss, Inc., & American Pharmaceutical Association.	
		Choi, et al., "Lactose-Poly (ethylene Glycol)-Grafted Poly-L-Lysine as Hepatoma Cell-Targeted Gene Carrier", Bioconjugate Chem., 1998, pages 708-718, vol. 9, Amerian Chemical Society.	
		Cortesi, et al., "Effecy of DNA Complexion and Freeze-Drying on the Physicochemical Characteristics of Cationic Liposomes", Antisense & Nucleic Drug Development, 2000, pages 205-215, vol. 10, Mary Ann Liebert, Inc.	
		Katayose, et al., "Remarkable Increase in Nuclease Resistance of Plasma DNA through Supramolecular Assembly with Poly (ethylene glycol)-Poly (L-lysine)", Journal of Pharmaceutical Sciences, 1998, vol. 87, no. 2, American Chemical Society and American Pharmaceutical Association.	
		Katayose, et al., "Water-Soluble Polyion Complex Associates of DNA and Poly (ethylene glycol)-Poly (L-lysine) Block Copolymer", Bioconjugate Chem., 1997, pages 702-707, American Chemical Society.	
		Kilcher, et al., "Influence of the DNA Complexation Medium on the Transfection Efficiency of Lipospermine/DNA Particles", Gene Therapy, 1998, pages 855-860, vol. 5, MacMillan Press LTD., Basingstoke, Great Britain.	
		Kwok, et al., "Strategies for Maintaining the Particle Size of Peptide DNA Condensates Following Freeze-Drying", International Journal of Pharmaceutics, 2000, pages 81-88, vol. 203, no. 1-2, Elsevier Science B.V.	
		Li, et al., "Lyophilization of Cationic Lipid-Protamine-DNA (LPD) Complexes", Journal of Pharmaceutical Sciences, 2000, pages 355-364, vol. 89, no. 3, Wiley-Liss, Inc., & American Pharmaceutical Association.	
		Noel, et al., "High Compacted DNA – Polymer Complexes Via New Polynorbornene Polycationic Latexes With Acetate Counterion", SCISEARCH Database, 2000, pages 8980-8983, vol. 16, no. 23, American Chemical Society, Washington, D.C.	
		Pðxon, et al., "The Effect of Lyophilization on Plasmid DNA Activity", Pharmaceutical and Development Technology, 2000, pages 115-122, vol. 5, no. 1, Marcel Dekker, Inc.	
		Toncheva, et al., "Novel vectors for gene delivery formed by self-assembly of NDA with poly (I-lysine) grafted with hydrophilic polymers", Biochemica et Biophysica Acta, 1998, pages 354-368, Elsevier Science B.V.	
		Vinogradov, et al., "Self-Assembly of Polyamine-Poly (ethylene glycol) Copolymers with Phosphorothioate Oligonucleotides", Bioconjugate Chem., 1998, pages 805-812, vol. 9, American Chemical Society.	
		Serres, et al., "DNA Condensation and Transfection of Cells in Culture by a New Polynorbornane Polycationic Polymer, Langmuir 1999, pages 6956-6950, Vol. 15, American Chemical Society	
		Wagner, et al., "Direct Evidence for Counterion Release upon Cationic Lipid- DNA Condensation, Langmuir 2000, pages 303-306, Vol. 16, American Chemical Society	
		Marschall, et al., "Transfer of YACs up to 2.3 Mb intact into human cells with polyethylenimine, Gene Therapy, 1999, pages 1634-1637, Vol. 6	

Examiner	Date	
Signature	Considered	
Olghalaic	33.13.13.13	

<sup>&#</sup>x27;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional), 2 Applicant is to place a check mark here if English language Translation is attached.